Pharma & Biotech Global Week in Review 9 Nov 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.


Highlights this week included:

UK Supreme Court: Industrial application and biotech patents: Human Genome Sciences v Eli Lilly (EPLAW) (IPKat) (IPKat) (Patently-O) (Sufficient Description) (IAM)


Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.



Linkage of marketing and legal theories for secondary pharma patents: seminar report (IPKat)

WHO’s Chan pitches UN agency’s “staying power,” unique role (IP Watch)

WHO board backs reform plan for UN agency (IP Watch)

WTO TRIPS Council: Intervention of the United States on implementation of Paragrah 6 of Doha Declaration (KEI)

Canada: WTO TRIPS Council: Canada’s defence of ACTA in discussions of “Trends in Enforcement” (KEI)

Canada: What does Human Genome Sciences v Eli Lilly mean for Canadian law?  (Sufficient Description)

EU: Suplementary protection certificates for combination products (JIPLP)

India: Ex-parte interim injunction passed against Symed Laboratories for infringement of Vifor’s patent (IIPRD Blog)

India: WTO TRIPS Council: India raises concerns on ACTA and TPPA on discussion of “Trends in the Enforcement of IPRs” (KEI)

India: WTO TRIPS Council: India questions the United States on eBay v. MercExchange precedent as alternative to Paragraph 6 mechanism (KEI)

UK: UKSC: Industrial application and biotech patents: Human Genome Sciences v Eli Lilly (EPLAW) (IPKat) (IPKat) (Patently-O) (Sufficient Description) (IAM)

US: Burr amendment to Senate FDA Approps Bill seeks FDA approval time transparency (FDA Law Blog)

US: Executive order aims to cure drug shortages (FDA Law Blog)



AndroGel (Testosterone) – US: Abbott Products, Unimed and Besins Healthcare file patent infringement complaint against Perrigo in response to Para IV certification filing (Patent Docs)

Cipro (Ciprofloxacin) – US: Court of Appeal hands down decision in the latest phase of the Cipro litigation (IP Whiteboard)

Dovonex (Calcipotriol) – US: District of Delaware rules that API manufacturer cannot be sued under section 271(e)(2): Leo Pharma v. Tolmar (Orange Book Blog)

Glivec (Imatinib) – India: Glivec patent dispute: the case so far – Part II (Patent Circle)

Morphine Sulfate – US: FDA prevails in 10th Circuit unapproved Morphine Sulfate case; court does not reach merits of grandfather claim (FDA Law Blog)

Nuvigil (Armodafinil) – US: Cephalon files patent infringement complaint against Breckenridge in response to Para IV certification (Patent Docs)

ReFacto (Antihemophilic factor) – US: Federal Circuit says regulatory patent term extension prolongs life of entire patent: Genetics Institute v. Novartis Vaccines & Diagnostics (Pharma Patents)

Singulair (Montelukast) – Spain: “Preparatory acts” and “offering for sale”: crossing the red light district (Kluwer Patent Blog)

Tamiflu (Oseltamivir) – India: A strange brew of Tamiflu and Swine flu (Spicy IP)

Valsartan – French court upholds ex parte preliminary injunction: Sanofi-Aventis France v Novartis (The SPC Blog)

Vimovo (Naproxen, Esomeprazole magnesium) – US: Astrazeneca files patent infringement suit in response to Anchen’s  Para IV challenge (Patent Docs)

Zymar (Gatifloxacin) – US: Senju files patent infringement complaint against Hi-Tech Pharmacal following Para IV certification (Patent Docs)

%d bloggers like this: